نتایج جستجو برای: meglimine antimoniate

تعداد نتایج: 365  

Journal: :Revista da Sociedade Brasileira de Medicina Tropical 2003
Bruna Pinheiro Silveira José Araújo Sobrinho Lacínia Freire Leite Maria das Neves Andrade Sales Maria do Socorro Araújo Gouveia Renato Leal Mathias Ricardo Amorim Guedes Filho Sônia Maria Barbosa

A case is reported of a 19-year-old woman, at week 24 of gestation, with visceral leishmaniosis. She was treated with meglumine antimoniate at a dose of 850 mg/day for 20 days. There occurred premature birth on day five of treatment and the neonate died one day after birth. Considering the importance of protozoiasis in our population and the rarity of the association with pregnancy, we resolved...

2017
Norberto Assis Membrive Flávio Jun Kazuma Thaís Gomes Verzignassi Silveira Jorge Juarez Vieira Teixeira Kárin Rosi Reinhold-Castro Ueslei Teodoro

The authors report a case of disseminated cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis, in a 55 years old patient with 1,119 lesions distributed throughout the body. The patient resides in Sabáudia municipality, North of Paraná State, Southern Brazil, where there was no previous report of this form of leishmaniasis. Treatment with meglumine antimoniate was successful, alt...

2009
R Yaghoobi S Maraghi

This case report states a 25-year-old woman, residing in the city of Dezfool, Khuzestan Province, south of Iran with the diagnosis of cutaneous leishmaniasis in June 2008. Her skin lesion had developed from 8 months earlier as a nodule on her left arm, 1×3 cm in diameter. Because of severity of the lesion, we prescribed meglumine antimoniate intralesionally with giving up her breast feeding. Af...

2011
Yann A. Meunier Michael K. Hole

We report the case of a six-year-old Brazilian girl referred for splenomegaly who first presented with fever, asthenia, and weight loss. Geographical location, clinical exam, and blood laboratories suggested kala-azar. Serology confirmed kala-azar diagnosis, but direct evidence of the parasites was not made. A treatment by meglumine antimoniate is given under hospital surveillance for two weeks...

Journal: :Trials 2006
Sandra Y Silva Ligia C Rueda Marcos López Iván D Vélez Christian F Rueda-Clausen Daniel J Smith Gerardo Muñoz Hernando Mosquera Federico A Silva Adriana Buitrago Holger Díaz Patricio López-Jaramillo

BACKGROUND Cutaneous Leishmaniasis is a worldwide disease, endemic in 88 countries, that has shown an increasing incidence over the last two decades. So far, pentavalent antimony compounds have been considered the treatment of choice, with a percentage of cure of about 85%. However, the high efficacy of these drugs is counteracted by their many disadvantages and adverse events. Previous studies...

Journal: :Analytical and bioanalytical chemistry 2002
N Miekeley S R Mortari A O Schubach

Results from a study are reported in which patients with leishmaniasis were monitored by whole blood, blood plasma, urine, and hair analysis, before, during, and after intramuscular administration of N-methyl meglumine antimoniate. Quadrupole ICP-MS was used for the detection of antimony and on-line ion chromatography for the separation of its species. After typically 30 consecutive daily injec...

Journal: :BMC Pharmacology 2002
Jaume Carrió Montserrat Portús

BACKGROUND Leishmaniasis is a common parasitic disease in Southern Europe, caused by Leishmania infantum. The failures of current treatment with pentavalent antimonials are partially attributable to the emergence of antimony-resistant Leishmania strains. This study analyses the in vitro susceptibility to pentavalent antimony of intracellular amastigotes from a range of L. infantum strains, deri...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید